FDA updates EUA for COVID-19 convalescent plasma
The Food and Drug Administration last week revised and reissued its emergency use authorization for COVID-19 convalescent plasma to treat hospitalized patients with COVID-19.
The changes include updates based on additional clinical trials; clarify the authorization’s limit to high-titer convalescent plasma for hospitalized patients early in the disease and those with impaired humoral immunity; and add to the tests acceptable for qualifying high-titer COVID-19 convalescent plasma.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…